Rufinamide
- Generic Name
- Rufinamide
- Brand Names
- Banzel, Inovelon
- Drug Type
- Small Molecule
- Chemical Formula
- C10H8F2N4O
- CAS Number
- 106308-44-5
- Unique Ingredient Identifier
- WFW942PR79
Overview
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Background
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Indication
治疗4岁以上及成人Lennox-Gastaut症候群的癫痫症。
Associated Conditions
- Lennox-Gastaut Syndrome
FDA Approved Products
Rufinamide
Manufacturer:Mylan Pharmaceuticals Inc.
Route:ORAL
Strength:200 mg in 1 1
Approved: 2021/06/15
NDC:0378-2330
Rufinamide
Manufacturer:Mylan Pharmaceuticals Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2021/06/15
NDC:0378-2331
Rufinamide
Manufacturer:Camber Pharmaceuticals, Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2021/06/02
NDC:31722-599
Rufinamide
Manufacturer:Hikma Pharmaceuticals USA Inc.
Route:ORAL
Strength:400 mg in 1 1
Approved: 2021/05/31
NDC:0054-0426
RUFINAMIDE
Manufacturer:Micro Labs Limited
Route:ORAL
Strength:400 mg in 1 1
Approved: 2023/05/17
NDC:42571-392
Singapore Approved Products
INOVELON FILM-COATED TABLET 200 MG
Manufacturer:Bushu Pharmaceutical Ltd. Misato Factory, Eisai Manufacturing Limited (Primary and Secondary Packager)
Form:TABLET, FILM COATED
Strength:200 mg
Online:Yes
Approved: 2017/01/05
Approval:SIN15146P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath